1. Updates on the Management of CINV From the 2014 June Congresses

2. Program Goals

3. Introduction

4. Introduction (cont)

5. 3 Major Classes of Antiemetic Agents Used in CINV Prevention

6. Antiemetic Guidelines: Current Recommendations

7. NK-1 RAs: Aprepitant

8. Investigational NK-1 RAs

9. Investigational NK-1 RAs (cont)

10. Aprepitant vs Metoclopromide in Delayed CINV

11. Rolapitant in Patients Receiving MEC Phase 3 Study Design

12. Rolapitant in Patients Receiving MEC Efficacy Results

13. Rolapitant in Patients Receiving MEC Safety

14. Rolapitant in Patients Receiving HEC Study Design of 2 Phase 3 RCTs

15. Rolapitant in Patients Receiving HEC Efficacy Results

16. NEPA: A Fixed Dose Oral Combination of Netupitant and Palonosetron Primary End Point Efficacy Results From 3 RCTs

17. NEPA + DEX vs Oral PALO + DEX in AC-based MEC Multinational, Randomized, Double-blind Phase 3 Study

18. NEPA + DEX vs Oral PALO + DEX in AC-based MEC Overall CR Rates Across Multiple Cycles

19. NEPA + DEX vs PALO + DEX in AC-Based MEC Safety Across Multiple Cycles

20. NEPA + DEX vs PALO + DEX in AC-based MEC Most Common TRAEs Across Multiple Cycles

22. Non-AC MEC

23. NEPA in Multicycle MEC and HEC Phase 3 Study Design

24. NEPA in Multicycle MEC and HEC Patient Baseline and Disease Characteristics

25. NEPA in Multicycle MEC and HEC Post-Hoc Analysis of No Emesis Rates (Cycle 1) in Patients Receiving Carboplatin

26. Fosaprepitant in Non-AC MEC Phase 3 Study Design

27. APF530 vs Palonosetron

28. Aprepitant in Pediatric Patients Phase 3 Study Design

29. The Problem of Nausea

30. Summary

31. Abbreviations

32. Abbreviations (cont)

33. References

34. References (cont)

35. References (cont)

36. References (cont)

37. References (cont)

38. References

39. References (cont)

40. References (cont)

41. References (cont)

42. References (cont)

43. References (cont)

44. References (cont)

45. References (cont)

46. References (cont)

47. References (cont)